RT Journal Article
SR Electronic
T1 Evaluation of the diagnostic value of YiDiXie™-SS and YiDiXie™-HS in colorectal cancer
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.20.24312286
DO 10.1101/2024.08.20.24312286
A1 Li, Xutai
A1 Sun, Chen
A1 Xiong, Rui
A1 Wu, Yutong
A1 Zhou, Huimei
A1 Ge, Zhenjian
A1 Li, Yingqi
A1 Chen, Wenkang
A1 Wang, Wuping
A1 Zhang, Pengwu
A1 Lin, Shengjie
A1 Chen, Siwei
A1 Li, Wei
A1 Lv, Guoqing
A1 Ji, Ling
A1 Lai, Yongqing
YR 2024
UL http://medrxiv.org/content/early/2024/08/20/2024.08.20.24312286.abstract
AB Background Colorectal cancer poses a severe risk to public health and has a substantial financial impact. Tumor markers such as CEA, CA125, CA19-9, and others, as well as the fecal occult blood test (FOBT), are frequently utilized for colorectal cancer screening and initial diagnosis. False-negative results of FOBT and other indicators, on the other hand, will cause treatment to be delayed, which will force patients to suffer from a poor prognosis, high treatment costs, a low quality of life, and a short survival period. False-positive results of FOBT and other indicators, however, will cause needless mental suffering, costly examination costs, examination injuries, and other unfavorable consequences. Finding practical, affordable, and non-invasive diagnostic techniques is crucial to lowering the false-positive and false-negative rates of FOBT and other indicators. The aim of this study was to evaluate the diagnostic value of YiDiXie™-SS and YiDiXie™-HS in colorectal cancer.Patients and methods This study eventually included 916 participants (602 in the malignant group and 314 in the benign group). Serum samples from individuals were obtained and examined using the YiDiXie™ all-cancer detection kit to assess the sensitivity and specificity of YiDiXie™-SS and YiDiXie™-HS, respectively.Results The sensitivity of YiDiXie™-SS was 99.0% (95% CI: 96.6% - 99.8%), 99.0% (95% CI: 96.4% - 99.8%), 100% (95% CI: 89.8% - 100%) and 98.6% (95% CI: 92.5% - 99.9%) in FOBT, CEA, CA125, and CA19-9 positive patients; and its specificity was 63.6% (95% CI: 43.0% - 80.3%), 65.0% (95% CI: 43.3% - 81.9%), 60.0% (95% CI: 23.1% - 92.9%) and 66.7% (95% CI: 35.4% - 87.9%), respectively. YiDiXie™-SS reduced false positives for FOBT, CEA, CA125, and CA19-9 by 63.6% (95% CI: 43.0% - 80.3%), 65.0% (95% CI: 43.3% - 81.9%), 60.0% (95% CI: 23.1% - 92.9%) and 66.7% (95% CI: 35.4% - 87.9%). YiDiXie™-HS demonstrated a sensitivity of 94.5% (95% CI: 87.8% - 97.6%), 93.7% (95% CI: 90.8% - 95.8%), 94.5% (95% CI: 92.2% - 96.2%) and 93.9% (95% CI: 91.5% - 95.7%) in FOBT, CEA, CA125, and CA19-9 negative patients, respectively; their specificities were 87.5% (95% CI: 69.0% - 95.7%), 86.7% (95% CI: 82.3% - 90.1%), 84.9% (95% CI: 79.1% - 89.3%) and 85.7% (95% CI: 81.1% - 89.3%). This indicates that 94.5% (95% CI: 87.8% - 97.6%), 93.7% (95% CI: 90.8% - 95.8%), 94.5% (95% CI: 92.2% - 96.2%) and 93.9% (95% CI: 91.5% - 95.7%) of false negatives for FOBT, CEA, CA125, and CA19-9 were reduced by YiDiXie™-HS, respectively.Conclusion YiDiXie™-SS lowers false-positive rates for FOBT, CEA, CA125, and CA19-9, with no increase in delayed treatment of malignant tumors. YiDiXie ™ -HS dramatically reduces false-negative rates for FOBT, CEA, CA125, and CA19-9. YiDiXie™-SS and YiDiXie™-HS offer significant diagnostic value in colorectal cancer and are predicted to address the two challenges of “high false-positive rate of FOBT and other indicators” and “high false-negative rate of FOBT and other indicators” in colorectal cancer.Clinical trial number ChiCTR2200066840.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialChiCTR2200066840Funding StatementThis work was supported by Shenzhen High-level Hospital Construction Fund, Clinical Research Project of Peking University Shenzhen Hospital (LCYJ2020002, LCYJ2020015, LCYJ2020020, LCYJ2017001).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of Peking University Shenzhen Hospital gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are contained in the manuscript.